Mochi Health is a telehealth platform that connects you with obesity medicine providers and dietitians who can prescribe GLP-1 weight loss medications and provide ongoing support, all through video visits and messaging. The service operates on a monthly subscription model starting at $79 per month, with medications priced separately.
How the Process Works
You start by choosing a board-certified obesity medicine provider and a registered dietitian from the platform. Your initial consultation happens over video, where the provider evaluates whether you’re a candidate for weight loss medication based on your health history, BMI, and goals. If prescribed medication, you can expect delivery within about 10 days of your first appointment.
From there, Mochi operates as an ongoing care relationship rather than a one-time prescription. Your membership includes unlimited video check-ins, structured follow-ups for dose adjustments and side-effect management, nutrition coaching sessions, and 24/7 messaging with your care team. This is designed to mirror what you’d get from an in-person obesity medicine clinic, just delivered virtually.
Who Qualifies for Medication
Mochi follows standard medical guidelines for prescribing weight loss medications. You’re generally eligible if your BMI is above 30, or above 27 with a weight-related condition like type 2 diabetes, high blood pressure, or high cholesterol. Your provider makes the final call during your consultation.
Lab work is not required to start or continue GLP-1 medications through Mochi. If you and your provider decide baseline testing would be useful, they can order common panels covering kidney function, liver enzymes, blood sugar, and cholesterol. But this is treated as a shared decision, not a prerequisite.
Medication Options and Costs
Mochi prescribes both brand-name and compounded versions of the major GLP-1 medications. Brand-name options include Ozempic, Mounjaro, and Rybelsus. On the compounded side, they offer both oral and injectable semaglutide as well as injectable tirzepatide.
Compounded medications have flat-rate pricing regardless of dose:
- Compounded semaglutide: $99 per month (covers all doses from 0.22 mg to 2.67 mg weekly, four doses per shipment)
- Compounded tirzepatide: $199 per month (covers all doses from 2.2 mg to 16.6 mg weekly, four doses per shipment)
Shipping is included in those medication prices. The flat-rate structure means your cost doesn’t increase as your provider adjusts your dose upward, which is a common frustration with other platforms that charge per-dose pricing.
Brand-name medications are priced through your pharmacy or insurance and aren’t included in Mochi’s flat rates.
Membership Pricing
The membership fee covers your medical care and is separate from medication costs. You have three options:
- Monthly: $79
- 3 months: $199 (about $66 per month)
- 12 months: $789 (about $66 per month)
That fee covers unlimited video appointments, messaging with your care team, dose adjustments, side-effect management, nutrition guidance, and help navigating insurance coverage. Mochi describes this as a pay-as-you-go model, meaning there’s no separate charge per visit.
Insurance and Prior Authorization
Mochi accepts insurance for brand-name medications and will handle prior authorizations on your behalf if your insurer requires them. If you have an in-network provider, your insurance may also cover some of the medical appointments. The platform includes what it calls “coverage education” to help you reduce out-of-pocket costs where possible.
Compounded medications are typically paid out of pocket since most insurers don’t cover them.
Availability
Mochi’s weight management program is available in all 50 states with licensed providers in each. Because everything runs through telehealth, your location only affects which providers are licensed to see you, not whether you can access the service.
A Note on Pharmacy Sourcing
One issue worth knowing about: in March 2025, Washington State health investigators raided Aequita, a compounding pharmacy closely affiliated with Mochi Health. Inspectors found the facility was using imported peptide base powder that its head of pharmacy operations acknowledged was six to nine times cheaper than American-made ingredients. The investigation also noted cost-cutting in shipping practices. This doesn’t necessarily reflect the current state of Mochi’s pharmacy partnerships, but it’s relevant context if you’re evaluating the platform’s compounded medication supply chain.